Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Neuphoria Therapeutics Inc. (Nasdaq: NEUP), a clinical-stage biotechnology company focused on developing innovative treatments for neuropsychiatric disorders, is set to present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City. The presentation will feature Dr. Spyros Papapetropoulos, the Company’s President and CEO, and will be available on demand starting September 5 at 7:00 a.m. ET on Neuphoria's website.

Neuphoria's flagship drug candidate, BNC-210, is a groundbreaking oral therapy designed as a selective negative allosteric modulator of the ?7 nicotinic acetylcholine receptor. It aims to provide timely relief for social anxiety disorder (SAD) and chronic post-traumatic stress disorder (PTSD). Unique in its class, BNC-210 seeks to restore neurotransmitter balance in the brain, offering rapid alleviation of anxiety and stress without the undesirable effects commonly associated with existing treatments, including sedation, cognitive impairment, or addiction potential.

The Company’s collaborative efforts with Merck & Co., Inc. further bolster its research capabilities, as they advance two drugs in early-stage clinical trials targeting cognitive deficits related to Alzheimer’s disease and related central nervous system conditions. In addition to BNC-210, Neuphoria is developing a pipeline of promising candidates, including next-generation therapies targeting the ?7 nicotinic acetylcholine receptor and preclinical programs focusing on Kv3.1/3.2.

Overall, Neuphoria Therapeutics is poised to make significant contributions to treating neuropsychiatric conditions, with innovative therapies that address unmet medical needs, paving the way for improved patient outcomes in this critical healthcare area. For more information, visit Neuphoria’s investor relations website or reach out via their contact details.

Neuphoria Therapeutics Inc. (Nasdaq: NEUP) is poised for a notable presence at the upcoming H.C. Wainwright 27th Annual Global Investment Conference, which could serve as a pivotal moment for the company and its stakeholders. As a clinical-stage biotechnology firm focused on neuropsychiatric disorders, Neuphoria's lead drug candidate, BNC-210, represents a promising advancement in treating conditions such as social anxiety disorder (SAD) and post-traumatic stress disorder (PTSD). The selective negative allosteric modulator has garnered attention for its potential to deliver rapid relief from anxiety without the adverse effects commonly associated with existing treatments, such as sedation and addiction.

Investors should keep an eye on the details shared during the presentation on September 8-10, as updates could significantly influence market sentiment regarding NEUP shares. The emphasis on BNC-210's unique mechanism and the backing of a strategic partnership with Merck & Co., Inc., further enhances Neuphoria’s credibility in the therapeutic landscape. This partnership not only adds resources but also underscores the potential scalability of Neuphoria’s innovations, particularly with additional drugs targeting cognitive deficits in Alzheimer’s disease in the pipeline.

Market participants should note the timing of the presentation, just days before the planned availability of the on-demand webcast. For investors considering entry or adjustment in their positions, monitoring trading volume and price movement leading up to and following the presentation could provide insights into market sentiment.

However, investors should also remain cautious. Clinical-stage biotechnology stocks can be highly volatile, and the outcomes of ongoing trials remain uncertain. Diversifying exposure and considering risk tolerance will be crucial strategies as Neuphoria seeks to capitalize on its innovative pipeline and capitalize on any favorable developments.